Metoclopramide Sugar-Free G.L. Pharma (Metoclopramide Hydrochloride)

Metoclopramide acts on the dopaminergic pathways that regulate nausea, vomiting and gastrointestinal motility.

• Nausea and vomiting: alleviates acute, postoperative or chemotherapy‑induced nausea and vomiting.
• Gastroparesis: enhances gastric emptying and reduces symptoms in delayed gastric emptying conditions.
• Gastro‑oesophageal reflux disease (GERD): decreases reflux episodes by improving gastric motility.
• Migraine‑associated nausea: controls nausea that accompanies migraine attacks.

• Metoclopramide competitively blocks dopamine D2 receptors in the chemoreceptor trigger zone of the brain and in peripheral gastrointestinal smooth muscle. This antagonism removes dopaminergic inhibition of gastrointestinal motility, thereby accelerating gastric emptying, and also diminishes the emetic signal from the trigger zone, producing anti‑emetic effects.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: feeling unusually tired or weak.
• Drowsiness: increased sleepiness, especially after dosing.
• Headache: mild to moderate cranial pain.
• Diarrhea: loose stools or increased bowel movements.
• Abdominal cramps: discomfort or pain in the stomach area.

Serious or Rare Side Effects

• Tardive dyskinesia: involuntary, repetitive movements that may be irreversible.
• Neuroleptic malignant syndrome: life‑threatening reaction with fever, muscle rigidity and autonomic instability.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Cardiac arrhythmias: abnormal heart rhythms.
• Seizures: convulsive episodes.
• Depression or suicidal thoughts: mood changes requiring immediate medical attention.

Before prescribing Metoclopramide, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Assess patient history: review for Parkinson’s disease, seizure disorders, depression, or previous extrapyramidal reactions.
• Monitor for extrapyramidal symptoms: observe for involuntary movements, rigidity or tremor during therapy.
• Avoid prolonged use: limit duration to the shortest effective period to reduce risk of tardive dyskinesia.
• Use with caution in elderly: older adults have increased susceptibility to central nervous system side effects.
• Store at ambient temperature: keep below 25°C, protect from moisture in the original packaging.

Metoclopramide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Anticholinergic agents: may diminish the pro‑kinetic effect of metoclopramide.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase metoclopramide plasma concentrations.
• Other dopamine antagonists: additive risk of extrapyramidal symptoms.
• MAO inhibitors: potential for hypertensive crisis when combined.
• Serotonergic drugs (e.g., triptans, SSRIs): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., alcohol, benzodiazepines): enhanced sedation and drowsiness.
• Antihistamines: may increase central nervous system depression.
• Antidiabetic agents: possible alteration of glucose control requiring monitoring.